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Background: Breast cancer is one of the most common cancers among women throughout the world. Therefore,
established cell lines are widely used as in vitro experimental models in cancer research.
Methods: Two continuous human breast cell lines, designated MBC1 and MBC2, were successfully established
and characterized from invasive ductal breast carcinoma tissues of Malaysian patients. MBC1 and MBC2 have been
characterized in terms of morphology analysis, population doubling time, clonogenic formation, wound healing
assay, invasion assay, cell cycle, DNA profiling, fluorescence immunocytochemistry, Western blotting
and karyotyping.
Results: MBC1 and MBC2 exhibited adherent monolayer epithelial morphology at a passage number of 150.
Receptor status of MBC1 and MBC2 show (ER+, PR+, HER2+) and (ER+, PR-, HER2+), respectively. These results are in
discordance with histopathological studies of the tumoral tissues, which were triple negative and (ER-, PR-, HER2+)
for MBC1 and MBC2, respectively. Both cell lines were capable of growing in soft agar culture, which suggests their
metastatic potential. The MBC1 and MBC2 metaphase spreads showed an abnormal karyotype, including
hyperdiploidy and complex rearrangements with modes of 52–58 chromosomes per cell.
Conclusions: Loss or gain in secondary properties, deregulation and specific genetic changes possibly conferred
receptor changes during the culturing of tumoral cells. Thus, we hypothesize that, among heterogenous tumoral
cells, only a small minority of ER+/PR+/HER2+ and ER+/PR-/HER2+ cells with lower energy metabolism might survive
and adjust easily to in vitro conditions. These cell lines will pave the way for new perspectives in genetic and
biological investigations, drug resistance and chemotherapy studies, and would serve as prototype models in
Malaysian breast carcinogenesis investigations.
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Breast cancer is the most common cancer among
women throughout the world. The number of newly-
diagnosed cases in 2008 was approximately 1.38 million,
and the number of deaths was more than 460,000 world-
wide [1].
Breast cancer is the most common cancer among
Malaysian women. The peak age for cancer cases among
the three major ethnic groups, namely Malay, Chinese
and Indian was between 40 to 49 years [2]. Malay
women presented larger tumours, in which 50% to 60%
were at the later stages (3 and 4), compared to other eth-
nic groups [3].
Though advances in breast cancer detection and treat-
ment have contributed to improving the rate of survival,
mortality rates remains significantly high. The establish-
ment of breast cancer cell lines is an important tool to
understand biological processes involved in this disease,
as well as the identification of potential therapeutic tar-
gets [4].
Cell lines are used to determine key initiation and pro-
gression factors in order to better understand a disease.
They are also used to predict the efficacy of novel thera-
peutic compounds. However, the cell lines currently used
for breast cancer are mostly derived from Caucasians or
African-Americans. Though breast cancer cell lines are
easy to handle and replaced from frozen stocks, they are
prone to genotypic and phenotypic drifts during consecu-
tive cultures [5,6].
Most in vitro studies using a few well-characterized
breast cancer cell lines such as MCF-7, MDA-MB-231,
T-47D and ZR-75-30 have been established for over 30
years. These cell lines were derived from tumor metasta-
ses especially aspirate or pleural effusions but not from
primary breast tumors [7-9].
The main objective of this study was to establish and
characterize two new immortalised Malaysian breast
cancer cell lines, which are derived from two fresh pri-
mary invasive ductal breast carcinoma tissues.
Materials and Methods
Cancer cell isolation and cell culture
Ethics approval and patient informed consent including
consent to participate in the study and consent to publish
was obtained for the present study in accordance to the
Universiti Kebangsaan Malaysia (UKM) Research and
Medical Ethics Committee (Approval No. FF-166-2004).
Two invasive ductal breast carcinoma tissues, one
from a Malay patient with triple negative (ER-, PR-,
HER2-) tumor and another from a Chinese patient with
(ER-, PR-, HER2+) tumor, were collected from Hospital
Universiti Kebangsaan Malaysia (HUKM). After surgical
removal, a portion of the primary breast tissues were im-
mediately placed in FBS-free DMEM (Sigma-Aldrich,USA) and were minced and scraped to isolate cancer
cells, in accordance to the manufacturer’s instructions of
the Cancer Cell Isolation Kit (Panomics, USA). The cells
were cultured in six-well culture plates supplemented with
10% FBS (Sigma-Aldrich, USA) and 3.7 g/L sodium bicar-
bonate (Sigma-Aldrich, USA) with a pH of 7.4 in a hu-
midified incubator with 5% CO2 at 37°C (IR Sensor,
Sanyo). Both cell lines were subcultured and then used to
determine the characteristics of the established cell lines.
Epithelial phenotype
The purity of the epithelial phenotype was confirmed by
staining with a pan-cytokeratin antiserum (FITC conju-
gate; Dako, Denmark).
Mycoplasma examination
Both MBC1 and MBC2 cell lines were cultured on cov-
erslips in 6-well plates and incubated overnight until
confluent. The coverslips were washed with PBS and fixed
with a fixative; then stained with DAPI and kept in the
dark place for 10 min. After that, the coverslips were
washed with distilled water and dried to detect myco-
plasma using a fluorescence microscope (Leica, Germany).
Population doubling time (PDT)
A total of 2 × 105 cells/ml of MBC1 and MBC2 cell lines
at passage 30 were cultivated for a period of 3 days (24,
48 and 72 hrs). Cell numbers were determined every 24
hrs using a Neubauer improved haematocytometer
(Sigma-Aldrich, USA) and cell numbers were counted in
triplicate. Population doubling time was calculated using
an online algorithm software provided at http://www.
doubling-time.com.
Clonogenic assay
A two-layer technique was used, with a base layer con-
sisting of 1% agar (BST TechLab, Malaysia), and a sec-
ond layer containing cells with 0.7% agar. Briefly, equal
volumes of the base agar (melted in a microwave oven
and cooled to 40°C in a water bath) containing 1% agar
along with 2X DMEM containing 20% FCS were mixed
to obtain 0.5% agar and 1X DMEM with 10% FCS. Sub-
sequently, 1.5 ml of the mixed solutions was added to a
petri dish (35 mm). The second layer, 3 ml of 2X DMEM
(20% FCS) and 3 ml of 0.7% agar were added to a centri-
fuge falcon tube and mixed gently. The cells were trypsi-
nised and counted to a ratio of 5 × 103 cells per plate.
After that, 1.5 ml was added to each petri dish (35 mm)
that was covered with the earlier agar base. The plates
were incubated for 14 days at 37°C and 5% CO2. Plates
were then stained with 0.5 ml of 0.005% crystal violet for
2 hrs and colonies were counted using an inverted
microscope Nikon Eclipse TS100 camera (Nikon DS-
Fi1). The cloning efficiency (CE) was calculated as the
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to each plate.
Wound healing assay (Migration assay)
The cell lines were seeded in 6-well plates until the cells
reach confluence. Then, a straight scratch was made using
a yellow plastic pipette tip. Next, the plates were rinsed
twice with PBS to remove floating cells. The underside of
the dish was marked to indicate the wounded area where
the initial photos were taken, which allowed the imaging of
both wound edges using the 10X objective at 6, 12, 18, 23
and 25 hrs. Subsequential images were periodically
recorded with an inverted phase microscope Nikon Eclipse
TS100 camera (Nikon DS-Fi1). The migration of cells
across the wounds was expressed as the percentage of
wound closure: Wound closure (%) = [(Initial areat0 - Final
areatf)/Initial areat0] ×100.
Matrigel invasion assay
The in vitro invasion assay was performed using Bio-
Coat Matrigel invasion assay system (BD Biosciences,
USA), according to the manufacturer’s instructions.
Invaded cells were counted under a light microscope
Nikon E600. The percentage of the invasion capability of
the cell lines was calculated as follows: Invasion (%)
=Number of cells attached to the lower side of the filter/
total number of cells × 100.
Genomic DNA preparation and PCR amplification
The genomic DNA from the cell lines was extracted
using a Qiagen kit (QIAamp DNA Mini Kit, Germany),
according to the manufacturer’s instructions. DNA yields
were quantified by Nano-drop (Thermo Nanodrop 2000)
and 1% agarose (Roche, Germany) gel electrophoresis to
determine the integrity of extracted DNA. The details of
the primer pairs for amplification of all 13 CODIS STR
alleles and Amelogenin in this study was assessed
according to the protocol previously described [10].
Non-denaturing polyacrylamide gel electrophoresis
To achieve adequate resolution for the separation of the
different STRs and Amelogenin alleles, large non-
denaturing 10% polyacrylamide gels were used, as explained
previously [10].
Western blotting
After protein extraction from the cell lines using pro-
tein extraction buffer (Pierce, USA), 30 μg of proteins
were separated by 12% SDS-PAGE (25 mA; 2 hrs). Pro-
teins were transferred to PVDF (Pierce, USA) mem-
branes using a Trans-Blot SD Semi-Dry Transfer Cell
(Bio-Rad, USA) at 15 V, 95 mA, for 1 hour. The PVDF
membrane was blocked using Blocker™ Casein (Pierce,
USA) for 1 hour at room temperature and then washedtwice using TBST. The membranes were then incubated
at 4°C overnight with primary antibodies, estrogen
mouse monoclonal antibody (1:1000; DAKO, Den-
mark), progesterone mouse monoclonal antibody
(1:1000; DAKO, Denmark), HER2 rabbit polyclonal
antibody (1:500; DAKO, Denmark) and β-actin mouse
monoclonal antibody (1:10000; DAKO, Denmark). The
membranes were then incubated for 1 hr at room
temperature with goat anti-mouse and goat anti-rabbit
secondary antibodies conjugated with alkaline phos-
phatase (i-DNA, USA) at a ratio of 1:1000 and then
washed twice with TBST for 10 minutes three times on
an orbital shaker. Then, blots were developed using the
BCIP/NBT (Santa Cruz, USA) solution for a period of
5–30 minutes to detect the target protein band as a pre-
cipitated dark blue colour.
Fluorescence immunocytochemistry of ER, PR and HER2
5×103 cells were seeded on coverslips in 6-well plates
and incubated at 37°C in a humidified CO2 incubator.
The cells were washed with PBS and incubated with 700
μL of 4% (v/v) paraformaldehyde for 15 min at RT and
then the cells were washed with PBS. Then, 700 μl of
antigen retrieval buffer (100 mM Tris, 5% (w/v) urea,
pH 9.5) was added to the wells for 10 min at 95°C and
washed twice with PBS. Next, 700 μl of permeabilisation
buffer (0.1% Triton X-100 in PBS) was added to the cells
for 15 minutes at RT and then washed with PBS. The
Blocking buffer (2% BSA) was added for 2 hrs and then
washed with PBS. The primary antibodies (DAKO,
Denmark) for estrogen, progesterone and HER2 was
added at a ratio of 1:35, 1:50 and 1:250, respectively and
left overnight, followed by washing with PBS. The goat
anti-mouse FITC secondary antibody (i-DNA, USA) for
ER and PR and the goat anti-rabbit FITC secondary anti-
body (i-DNA, USA) for HER2 were added for 1 hour at
RT, incubated away from light and then washed twice
with PBS. Finally, mounting buffer (Glycerol: PBS; 9:1)
was used to mount coverslips on the slides to visualise
ER, PR and HER2 expression under a fluorescent micro-
scope (Leica, Germany).
Determination of S-phase by the PI
Both cell lines were harvested and washed with 1X PBS;
then, the cell pellets were fixed with pre-stored 90%
ethanol at −20°C and were then incubated overnight at
−20°C (0.5 ml). After incubation, cells were spun down
at 800 rpm for 5 min. The supernatant was carefully dis-
carded and the cells were resuspended by tapping until
the pellet was fully dissolved. The cells were then
washed in 1X PBS at 2000 rpm for 5 min. Again, super-
natant was carefully discarded and the cells resuspended
in 450 μl of pre-warmed 1X PBS and 25 μl of 10 mg/ml
RNase at 37°C. After that, 50 μl of 1 mg/ml propidium
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and mixed well in an incubator for 30 min at 37°C. Fi-
nally, the stained samples were analysed using a FACS
LSR FORTESSA flowcytometer which excites at 488 nm.
The proliferation index (P.I.) was calculated by following
formula P.I. = (S+G2M)/G0G1.
Metaphase spread
The cell lines were seeded in DMEM medium to reach
70% confluent. Then, 50 μl of 10 μg/ml colcemid (GIBCO,
USA) was added to the culture medium in a humidified
incubator with 5% CO2 at 37°C for 2 hrs. Both media and
trypsinised cells were centrifuged at 900 rpm for 5 min.
The supernatant was decanted and the pellet was dis-
persed by tapping gently. Five ml of pre-warmed hypo-
tonic solution (0.4% KCl and 0.4% Sodium Citrate; 1:1)
were added drop by drop and incubated at 37°C for 15
min. Ten drops of fresh cold fixative methanol (Merck,
Germany) and acetic acid (Merck, Germany) with a ratio
of 3:1 were added while gently mixing. The tube wasFigure 1 Morphology of the MBC1 and MBC2 Cell Lines. Panels (A) an
MBC2-PN-2, respectively; panels (C) and (D) represent breast cancer MBC1-
PN: passage number.placed on ice for 15 min and centrifuged at 1000 rpm for
5 min. The supernatant was discarded and the pellet was
re-washed with 5 ml fixative. After that, the supernatant
was decanted and 200 μl of fixative was added. Next, a
maximum of 3 drops of the suspended cells were dropped
carefully from a height of approximately 0.5 meters onto
the slide, and left at room temperature overnight to dry.
The slides were stained with Giemsa (GIBCO, USA) work-
ing solution for 3–5 min and rinsed with distilled water.
The slides were air-dried and then analysed.Statistical analysis
Analyses were performed using the Statistical Analysis
System (SAS Institute 2003). The data were presented as
mean ± standard deviation. It was analysed using the
ANOVA procedure of SAS. Significant differences were
further separated using Duncan’s multiple range test.
Differences with a value of p<0.05 were considered to be
statistically significant.d (B) represent breast cancer MBC1-PN-2 and
PN-125 and MBC2-PN-85, respectively. Magnification, 40X;
Figure 2 Soft-agar Colony Formation Assay (Clonogenic Assay) of the MBC1 and MBC2 Cell Lines at 14 Days after Seeding. Panels (A)
and (B) represent MBC1 and MBC2 cell lines, respectively. Magnification, 10X.
Figure 3 Comparison of Colony Formation Rates of the MBC1
and MBC2 Cell Lines. Cell colony numbers were determined in
triplicates where the both cells showed no significant differences
(p>0.05). Error bars represent the mean ± SD.
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Histopathology study
Histological examination of the breast tissues showed
that ER, PR and HER2/neu status of tumoral tissue for
MBC1 was ER-, PR- and HER2- (Triple negative), while
for MBC2 was ER-, PR- and HER2+ (Data not shown).
Morphology and culture of primary breast cell lines
The population doubling time (PDT) of the first passage
for the MBC1 and MBC2 was approximately 30 days after
the initiation of culture. The morphology (Figure 1) of the
two established human breast cell lines and the purity of
the epithelial cells (data not shown) of the MBC1 and
MBC2 human breast cell lines were determined. The
growth medium for both MBC1 and MBC2 consisted of
DMEM supplemented with 10% FBS and kept in a hu-
midified incubator with 5% CO2 at 37°C. Cells were main-
tained in culture until passages 150, and then kept in
liquid nitrogen. None of these established cell lines exhib-
ited any signs of senescence and they were therefore con-
sidered immortalized. No sign of contamination, such as
mycoplasma, fungi, or bacteria was observed.
Clonogenic assay
The MBC1 and MBC2 cell lines were able to produce
colonies on the plate with similar cloning efficiencies
(CE) of 1.074% and 1.048%, respectively (Figure 2). Both
MBC1 and MBC2 cell lines produced a colony size of
approximately 95–110 μm in diameter after 14 days on
the soft agar. The cells also showed no significant differ-
ence (p>0.05) in the colony formation rate (Figure 3).
Wound healing assay (Migration assay)
The migration of MBC1 and MBC2 cell lines across the
wounds was calculated as a percentage of wound closure.The growth rates of wound-healing assays for MCF-7 and
MBC2 showed the highest and lowest growth rates
in vitro wound-healing assays, respectively (Figure 4A, B).Matrigel invasion assay
The invasion percentage of MBC1, MBC2 and MCF-7 were
0.110%, 0.040% and 0.116%, respectively (Figure 5, A-F).
No significant differences were observed between MBC1
and MCF-7 (p>0.05), indicating the similar invasion ability
of the MBC1 and MCF-7 cell lines to migrate through and
adhere to the lower side of the filter in vitro condition.
However, MBC2 demonstrated lower invasion activity com-
pared to the MBC1 and MCF-7 (p<0.05) (Figure 6).
AB
Figure 4 (See legend on next page.)
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Figure 4 A: Wound Healing Assay of the MBC1, MBC2 and MCF-7 Cell Lines at 0, 6 and 12 hrs of Culturing. The result of growth rates in
wound healing assays increased in the order of MBC2 < MBC1 < MCF-7, respectively. Magnification, 40X. B: Wound Healing Assay of the MBC1
and MBC2 Cell Lines at 18, 23 and 24–26 hrs of Culture. The result of growth rates in wound healing assays increased in the order of MBC2 <
MBC1 < MCF-7, respectively. Magnification, 40X.
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The growth kinetics and the corresponding doub-
ling time at 0, 24, 48 and 72 hrs of incubation for
the MBC1 and MBC2 cell lines were determined at
passage 30. The PDT of the MBC1 and MBC2Figure 5 Matrigel Invasion Assay of MBC1 and MBC2 Cell Lines as Co
MBC1, and panels (C) and (D) indicate the invasion activity of MBC2. Panels
control. Magnification of panels A, C & E is 10X; B, D & F is 40X.were 30.14 hrs and 35.6 hrs. The growth rate
coefficients for the MBC1 and MBC2, representing
the number of doublings per unit of time, were
0.023 (2.3%) and 0.0195 (1.95%), respectively
(Figures 7A, B).mpared to MCF-7. Panels (A) and (B) show the invasion activity of
(E) and (F) demonstrate the invasion activity of MCF-7 as positive
Figure 6 Invasion Rates of the MBC1 and MBC2 Cell Lines as
Compared with MCF-7. Error bars indicate mean ± SD.
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DNA profiling using STR markers and Amelogenin of
the cells were visualized on 10% polyacrylamide gels
using silver staining method (Figure 8). The PCR prod-
uct sizes were determined using Labworks software
(UVP). No amplification was observed for the D3S1358,
D5S818 and D13S317 loci in the MBC1 cells on poly-
acrylamide gel electrophoresis (PAGE), while all loci
were amplified in the MBC2 cell line (Table 1).
Western blotting
ER expression was detected in the MBC1 and MBC2
cells and MCF-7 (as positive control). No band was
observed for the MDA-MB-231(as negative control). Im-
munoblotting indicated the expression of PR for the
MBC1 cells, but not expressed for the MBC2, while both
MBC1 and MBC2 were positive for the expression of
HER2. All cell lines expressed clear and distinct bands of
β-actin, indicating the integrity of the assay (Figure 9).
Fluorescence immunocytochemistry
Fluorescence ICC shows the presence of ER in the
MBC1, MBC2 and MCF-7 as localised nuclear staining
pattern. ICC/IF analysis also revealed the expression of
progesterone receptors (PR) in the MBC1 and MCF-7
cells with the same localised pattern. However, the
MBC2 cell line was shown to be PR negative compared
to MCF-7. The expression of HER2 receptor was further
observed by fluorescence ICC in the cell membrane of
the MBC1, MBC2 and MDA-MB-453 cell lines (Figures 10,
11, 12).
Cell cycle analysis
The number of the MBC1 cells showed an increase in
the S-phase on the FCM histogram. The proliferationindices (P.I.) of the MBC1 cell line (P.I. 0.61) was ap-
proximately two times higher than the MBC2 (P.I. 0.32),
indicating a more proliferative phenotype in the MBC1
cell line than MBC2 (Figure 13, Table 2).
Cytogenetic analysis
The G-banding karyotype of the metaphase spread was
carried out. Karyotype analysis of the cells with the dif-
ferent cell passages revealed structural and numerical
chromosomal abnormalities with chromosome numbers
of 46 to 90, in which the majorities show a range of
chromosomes between 52 to 58 including several un-
identified chromosomes (Figure 14).
Discussion
Both MBC1 and MBC2 are the first breast cancer cell
lines established from Malaysian primary breast cancer
tissues through spontaneous immortalization. The estab-
lished cell lines grow as monolayers, adherent with con-
sistent morphologically during subsequent cultures up to
150 passages, without any changes in the epithelial
morphology such as MCF-7 and MDA-MB-231. Accord-
ing to data on other human primary cells, the senescence
period of cells undergoing cycle arrest varies from 1 to 8
weeks [11]. However, both MBC1 and MBC2 cell lines
bypassed this critical phase spontaneously after 4–5 weeks.
The MBC1 and MBC2 cell lines were able to grow in
a defined DMEM medium [12] without any extra essen-
tial components, elements, or hormones. This is in con-
trast to for example, MCF-10A cell line requiring
cholera toxin; MCF-7 and T-47D needing bovine insulin;
and MDA-MB-435S needing ATCC-formulated Leibo-
vitz’s L-15 Medium with bovine insulin and glutathione
for growth [7,9,13,14].
The more established breast cancer cell lines such as
MDA-MB-231 and MCF-7 were derived from malignant
effusions [15] which may genetically differ from the ori-
ginal tumour [16,17]. However, the breast cancer cells,
MBC1 and MBC2, were derived from primary infiltrat-
ing ductal breast tumours, the most frequently observed
histological type [18]. Cells derived from primary breast
tumours have a lower chance of establishment compared
to cell lines derived from metastatic sites or pleural effu-
sion [13].
The PDT of the MBC1 cells (30.14 hrs) is comparable
with the established Italian BRC-230 breast cancer cell
line [19] and French human breast cell line VHB-1 [20]
with the PDT of 30.5 and 30 hrs, respectively; while the
PDT of MBC2 (35.6 hrs) is similar to the Chinese BC-
019, BC-020 breast cancer cell lines with the PDT of 36
hrs and 35 hrs, respectively [21]. The PDT of MBC1 and
MBC2 is higher than the Italian breast cancer cell lines
MAST, MA2 and MA3 with a PDT of 68, 70 and 78 hrs
[22]; the human breast cancer cell lines UACC-812 and
AB
Figure 7 A: Population Doubling Time (PDT) of the MBC1 Cell Lines. Proliferation of the MBC1 was analysed by counting the total cell
number at 0, 24, 48 and 72 time points. MBC1 proliferates in vitro with a PDT of 30.14 hours. B: Population Doubling Time (PDT) of the MBC2 Cell
Lines. Proliferation of the MBC2 was analysed by counting the total cell number at 0, 24, 48 and 72 time points. MBC2 proliferates in vitro with a
PDT of 35.6 hours.
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A B
Figure 8 Polyacrylamide Gel Electrophoresis of 13 CODIS STR Loci and Amelogenin for the MBC1 (Panel A) and MBC2 (Panel B) Cell
Lines. (Panel A): M: DNA molecular size marker. Lanes 1:[Amelogenin (106 bp), FGA (185 bp, 193 bp)], 2:[D8S1179 (165 bp)], 3:[D16S539 (290 bp)],
4:[D18S51 (292 bp)], 5:[CSF1PO (304 bp, 324 bp)], 6:[TH01 (181 bp, 185 bp), TPOX (225 bp, 236 bp)], and 7:[VWA (145 bp, 150 bp), D21S11 (213 bp,
218 bp)]. (Panel B): M: DNA molecular size marker. Lanes 1:[Amelogenin(106 bp), FGA(190 bp)], 2:[D8S1179 (171 bp, 179 bp), D7S820 (239 bp)], 3:
[D3S1358 (122 bp, 124 bp), D16S539 (284 bp, 291 bp)], 4:[D13S317 (169 bp, 173 bp), D18S51(289 bp, 304 bp)], 5:[D5S818 (133 bp, 139 bp),
CSF1PO (302 bp, 310 bp)], 6:[TH01 (189 bp, 193 bp), TPOX (232 bp], and 7:[VWA (122 bp), D21S11 (228 bp, 240 bp)].
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cell lines ZR-75-1, ZR-75-27, and ZR-75-30 from the
malignant effusions of breast cancer with PDT of 80
hrs, 144 hrs and 110 hrs, respectively [24]. According
to the results obtained by other researchers, one of theTable 1 Allele assignment analysis of the amplified STR
Loci and Amelogenin for the MBC1 and MBC2 Cell Lines
STR locus MBC1 MBC2
CSF1PO 10, 15 9, 11
FGA 19, 21 20
TH01 4, 5 6, 7
TPOX 6, 9 8
VWA 15, 17 10
D3S1358 -† 14, 17
D5S818 -† 10, 11
D7S820 13 11
D8S1179 9 10, 12
D13S317 -† 8, 9
D16S539 12 9, 11
D18S51 14 13, 17
D21S11 26, 27 30, 33
AMEL X, X X, X
† No STR loci identified for the MBC1 cells.main reasons for the different PDTs of cell lines is the
differences in cellular content rather than differences in
the rates of proliferation [25]. The enhancement of the
population doubling in vitro in the MBC1 and MBC2
human breast cell lines may be due to the existence
and activity of tumourigenic stem cells [26] or most
likely arises from the selection of faster-growing sub-
clones from an initially heterogeneous population
through frequent and incomplete trypsinisation of the
cultures [27].
Both MBC1 and MBC2 cell lines produced a colony
size of approximately 95–110 μm in diameter after day
14 on soft agar. Depending on the cell line and incuba-
tion time, different colony sizes have been reported.
For instances, MCF-7 cell line forms 75–100 μm col-
onies after 11 days of growth and 100–200 μm in diam-
eter by 21 days; T-47D cells form well-defined colonies
with diameters of 80 μm by day 14 and 120 μm by day
21; MaTu cells grow well in soft agar with colony sizes
of 50–75 μm diameters and sometimes greater than
100 μm diameters; MT-1 cells grow rapidly into colonies
typically 70 μm in diameter by 11 days. However, some cell
lines such as MT-3 and HS578T do not grow well in soft
agar and therefore form only small colonies in the plate
while some others like MC4000 cells produced no col-
ony growth in soft agar [25].
Figure 9 Detection of ER, PR, HER2 and β-actin expression in various breast cancer cell lines by western blotting.
Figure 10 Expression of ER in MBC1 and MBC2 Cell Lines, with MCF-7 as a Positive Control. The expression of ER was shown in the MBC1-
PN-120, MBC2-PN-85 and MCF-7 (as a positive control) with a localised nuclear staining pattern. Magnification, 20X.
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Figure 11 Expression of PR in MBC1 and MBC2 Cell Lines, with MCF-7 as a Positive Control. ICC/IF showed the expression of PR receptor
with a localised nuclear staining pattern in the MBC1-PN-120 and MCF-7(as a positive control) but not in MBC2-PN-85. Magnification, 20X.
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the MBC2 cells compared to the MBC1 and MCF-7 as
a control. The MBC1 cell line had similar growth rates
with the control cell line MCF-7 in wound healing
assay.
The results of entire 13 CODIS core STR loci were
compared with the well-characterised and validated
references provided by ATCC and JCRB, and those pre-
viously reported [10]. The two established cell linesFigure 12 Expression of HER2 in MBC1 and MBC2 Cell Lines, with MD
localised staining pattern in the cell membranes was shown in the MBC1-P
Magnification, 20X.have neither homology to each other nor with other
STR-profiled breast cell lines, demonstrating the lack
of any cross-contamination of cell lines with other
studied cell lines such as MCF-7 [7], MDA-MB-231
[28], HeLa, HepG2, KB and MRC-5 [10]. DNA profiling
using STR markers also confirmed the gender of
tumour origin of MBC1 and MBC2 cell lines.
Expression studies revealed remarkable expression of
HER2 protein in both established cell lines. The MBC1A-MB-453 as a Positive Control. The expression of HER2 with a
N-120, MBC2-PN-85 and MDA-MB-453(as a positive control).
Figure 13 Cell Cycle Analysis of the MBC1 and MBC2 Cell Lines by Flow Cytometry Histogram. Enhancement in the S-phase fraction (SPF)
demonstrates an unusual activity level of MBC1 proliferation compared to MBC2.
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http://www.cancerci.com/content/12/1/43cell line was also shown to be ER+/PR+ while the MBC2
was ER+/PR- based on mRNA expression profiling. How-
ever, the tumour origins were shown ER-/PR-/HER2- and
ER-/PR-/HER2+ for the MBC1 and MBC2 cells, respect-
ively. This may be due to a gain in secondary properties
after culturing or that the MBC1 and MBC2 cells were
derived from a small minority of ER+/PR+/HER2+ and
ER+/PR-/HER2+ cells, respectively. The mechanism of
this gain or loss during carcinogenesis is largely un-
known but a very feasible hypothesis suggests a possible
relationship between such deregulation and specific gen-
etic changes [29].
Hence, these changes could be attributed to the War-
burg effect, defined as an increased dependence on gly-
colysis for ATP synthesis, even in the presence of
abundant oxygen, instead of a cell using the more effect-
ive pathway of OXPHOS [30]. The Warburg effect has
been consistently observed in a wide spectrum of human
cancers, and has been directly linked to the activation of
oncogenes, and loss of tumor suppressor genes, which
result in the deregulated conversion of glucose to lactate.
Among the possible mechanisms, mitochondrial mal-
function and hypoxia in the tumor microenvironment
are considered two major factors contributing to the
Warburg effect [31,32].Table 2 Comparison of DNA ploidy and cell cycle measureme
MBC1
Diploid
(83.68%)
G0/G1 61.88%
S 30.12%
G2/M 8%
Proliferation Index (P.I.) 0.61The MBC1 and MBC2 cells showed an SPF of 30.12%
and 16.76% with proliferation index (PI) of 0.61 and
0.32, respectively, indicating a proportion of MBC2 cells
were arrested in the G0/G1 phase, delaying the progres-
sion of the cell cycle and inhibiting cell proliferation
compared to the MBC1.
The karyology study of the MBC1 and MBC2 cells
demonstrated hyperdiploidy and complex rearrangement
of their chromosomes. The fractured chromosomes were
observed in different numbers in the MBC1 and MBC2.
The hyperdiploidy (> 50 chromosomes) may arise from
the fracture of the chromosomes. Cytogenetic analysis of
MBC1 and MBC2 revealed an extensively rearranged
hyperdiploid karyotype with unidentified chromosomes
and a modal chromosome number of 52–58.
Conclusions
Receptor changes may be due to loss or gain in secondary
properties, activation of cancer stem cells and unknown
specific genetic changes in tumoral cells. Regardless of re-
ceptor status, we hypothesize that, among heterogenous
tumoral cells, only cells with low energy metabolism
might survive and adjust easily to in vitro conditions. This
is to date the first isolation and establishment of immorta-
lised Malaysian primary breast cancer cell lines. Breastnts of the MBC1 and MBC2 cell lines
MBC2
Tetraploid Diploid Tetraploid
(16.32%) (92.68%) (7.32%)
%100 75.24% 100%
%0 16.76% 0%
%0 8% 0%
0.32
Figure 14 Chromosomal Distribution Pattern of the MBC1 and MBC2 Cell Lines in 100 Metaphase Spreads. A high percentage of the
metaphase spreads showed chromosome numbers ranging from 52–58 in both MBC1 and MBC2 cell lines.
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http://www.cancerci.com/content/12/1/43cancer cell lines which are currently used are mostly
derived from the Caucasian population. The accessibility
of two newly established human breast cell lines, MBC1
and MBC2, could provide us the important tools and
new experimental models to study the gene expression
patterns, efficacy of therapeutic drugs and prognostic
and diagnostic markers, pathogenic mechanisms and
biological behaviour of breast cancer in vitro and
in vivo. These cell lines could also provide the ground-
work to further investigate the activity of new anti-
tumour agents in mono- or polychemotherapy in vitro
or to elucidate the mechanisms of drug resistance in
breast cancers in the future. They also would serve as
prototype models of Malaysian breast carcinogenesis.
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